{
    "id": 997,
    "fullName": "CTLA4 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type CTLA4 indicates that no mutation has been detected within the CTLA4 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1493,
        "geneSymbol": "CTLA4",
        "terms": [
            "CTLA4",
            "ALPS5",
            "CD",
            "CD152",
            "CELIAC3",
            "CTLA-4",
            "GRD4",
            "GSE",
            "IDDM12"
        ]
    },
    "variant": "wild-type",
    "createDate": "07/15/2014",
    "updateDate": "01/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11077,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AGEN1884 treatment resulted in disease progression in 54% (6/11) of patients with advanced solid tumors, however, 45% (5/11) of patients continued with the study and a partial response of an 80% reduction was confirmed in one patient with angiosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 3075)).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 5695,
                "therapyName": "AGEN1884",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9069,
                    "pubMedId": null,
                    "title": "Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193189.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11078,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AGEN1884 treatment resulted in disease progression in 54% (6/11) of patients with advanced solid tumors, however, 45% (5/11) of patients continued with the study and a partial response of an 80% reduction was confirmed in one patient with angiosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 3075)).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 5695,
                "therapyName": "AGEN1884",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9069,
                    "pubMedId": null,
                    "title": "Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193189.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1482,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I and Phase II clinical trials, treatment with the CTLA4 blocking antibody Tremelimumab resulted in tumor regression in patients with metastatic melanoma (PMID: 23748107).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1377,
                    "pubMedId": 23748107,
                    "title": "CTLA-4 blockade and the renaissance of cancer immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23748107"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5251,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Yervoy (ipilimumab) demonstrated safety and preliminary efficacy in pediatric patients with advanced solid tumors, resulting in stable disease in 18% (6/33) of patients (PMID: 26534966).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4960,
                    "pubMedId": 26534966,
                    "title": "Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26534966"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1061,
            "profileName": "CTLA4 wild-type",
            "profileTreatmentApproaches": [
                {
                    "id": 5377,
                    "name": "Ipilimumab",
                    "profileName": "CTLA4 wild-type"
                },
                {
                    "id": 5376,
                    "name": "Tremelimumab",
                    "profileName": "CTLA4 wild-type"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}